February 4, 2010 Cannasat Announces Signing of Letter of Intent for In-licensing of Parkinson’s Disease Technology Read More >		February 1, 2010 Cannasat Update From Anthony Giovinazzo, President & CEO Read More >
		January 11, 2010 Cannasat Therapeutics Strengthens its Board of Directors Read More >		December 22, 2009 Cannasat Therapeutics Announces Debt for Shares Settlement Read More >
		November 16, 2009 Cannasat Therapeutics Announces New Chief Executive Officer: Anthony J. Giovinazzo, M.B.A., C.Dir. Read More >		August 31, 2009 Cannasat Therapeutics Completes Prospectus Offering Read More >
				Press Release Archive

Cannasat is a specialty clinical development pharmaceutical company targeting diseases of the brain. Cannasat has a proprietary formulation technology for cannabinoid drug candidates, which may be used to treat neuropathic pain associated with multiple sclerosis and cancer, as well as for nausea/vomiting and appetite stimulation.